Idenix Pharmaceuticals (IDIX)

[DewDiligence]

Here’s a brief excerpt from Forbes/AP on Viread vs
Hepsera. As noted in #msg-21399563, Viread is priced
at a discount to Hepsera, which will pinch GILD’s
margins when Viread begins to supplant Hepsera.

http://www.forbes.com/2007/07/20/gilead-atripla-hiv-markets-equity-cx_ra_0720markets35.html

>>
“The other concern [Gilead] investors have…is that Gilead has completed two phase III trials of the drug Viread for Hepatitis B and found that Viread is superior to Hepsera, a more expensive drug Gilead currently has on the market. The fear is that Viread will cannibalize the market for Hepsera and profitability will fall,” Sieler said. “I think this is a mistake because Gilead has been losing new patient share to those new drugs for Heptitis B from other companies and Gilead needs a stronger competitor themselves to maintain their new market share.”
<<